With more and more people receiving their COVID-19 vaccine doses in Japan, sales of fever and pain relievers are also expanding sharply. The number of people taking such drugs after experiencing negative reactions from novel coronavirus vaccines is believed to be rising.
According to the health ministry’s guidelines, moderately ill COVID-19 patients are divided into the Moderate I and II groups. Moderate I patients have a short breath and show signs of pneumonia, while Moderate II patients suffer severer symptoms and need oxygen administration. The new policy would keep Moderate I patients at home.